The FDA submission training no one talks about The day a mid-stage biotech team handed me their IND package, I saw their confidence crumble when I asked, *”Have you ever practiced explaining your clinical endpoint to a reviewer who’s seen 200 of them this month?”* Their silence spoke volumes. They’d memorized the CFR, highlighted every […]